Enterome Information

Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body. The company is currently developing a pipeline of drug candidates consisting of OncoMimics™ peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign safety profile with encouraging early signs of efficacy. EO2401 has successfully completed a Phase 2 clinical trial in patients with recurrent glioblastoma, and Enterome is currently seeking a pharmaceutical partner to further develop a pivotal trial.